Trials / Recruiting
RecruitingNCT05064540
JAGUAR Trial: ObJective Analysis to GaUge EVAR Outcomes Through Randomization
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 450 (estimated)
- Sponsor
- Endologix · Industry
- Sex
- All
- Age
- 21 Years
- Healthy volunteers
- Not accepted
Summary
Prospective, randomized, multi-center study designed to evaluate the outcomes of commercially available contemporary EVAR in a real-world population. Patients will be randomized into two device cohorts and compared across the primary endpoints. Patients will be followed procedurally to discharge, at 1, 6, 12 months and annually through to 5 years (total follow-up commitment).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Alto Abdominal Stent Graft System | Endovascular Abdominal Aneurysm Repair (EVAR) using commercially available, FDA approved endovascular graft systems implanted. |
| DEVICE | FDA Approved EVAR AAA Graft Systems | FDA approved comparator of choice |
Timeline
- Start date
- 2021-09-20
- Primary completion
- 2031-03-01
- Completion
- 2031-03-01
- First posted
- 2021-10-01
- Last updated
- 2025-06-08
Locations
29 sites across 1 country: United States
Regulatory
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT05064540. Inclusion in this directory is not an endorsement.